Literature DB >> 26437872

Clinical development of RTS,S/AS malaria vaccine: a systematic review of clinical Phase I-III trials.

Selidji T Agnandji1,2, José F Fernandes1,2, Emmanuel B Bache1,2, Michael Ramharter1,2,3.   

Abstract

The first clinical Phase III trial evaluating a malaria vaccine was completed in December 2013 at 11 sites from seven sub-Saharan African countries. This systematic review assesses data of Phase I-III trials including malaria-naive adults and adults, children and infants from malaria endemic settings in sub-Saharan Africa. The main endpoint of this systematic review was an analysis of the consistency of efficacy and immunogenicity data from respective Phase I-III trials. In addition, safety data from a pooled analysis of RTS/AS Phase II trials and RTS,S/AS01 Phase III trial were reviewed. The RTS,S/AS01 malaria vaccine may become available on the market in the coming year. If so, further strategies should address challenges on how to optimize vaccine efficacy and implementation of RTS,S/AS01 vaccine within the framework of established malaria control measures.

Entities:  

Keywords:  AS01; AS02; RTS,S/AS; anti-CSP; anti-HBs; geometric mean concentration; immune responses; vaccine efficacy

Mesh:

Substances:

Year:  2015        PMID: 26437872     DOI: 10.2217/fmb.15.90

Source DB:  PubMed          Journal:  Future Microbiol        ISSN: 1746-0913            Impact factor:   3.165


  21 in total

1.  Systems analysis of protective immune responses to RTS,S malaria vaccination in humans.

Authors:  Dmitri Kazmin; Helder I Nakaya; Eva K Lee; Matthew J Johnson; Robbert van der Most; Robert A van den Berg; W Ripley Ballou; Erik Jongert; Ulrike Wille-Reece; Christian Ockenhouse; Alan Aderem; Daniel E Zak; Jerald Sadoff; Jenny Hendriks; Jens Wrammert; Rafi Ahmed; Bali Pulendran
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-13       Impact factor: 11.205

2.  Immunization of Malaria-Preexposed Volunteers With PfSPZ Vaccine Elicits Long-Lived IgM Invasion-Inhibitory and Complement-Fixing Antibodies.

Authors:  Isabelle Zenklusen; Said Jongo; Salim Abdulla; Kamaka Ramadhani; B Kim Lee Sim; Hayley Cardamone; Erika L Flannery; Thao Nguyen; Matthew Fishbaugher; Ryan W J Steel; Will Betz; Nelly Carmago; Sebastian Mikolajczak; Stefan H I Kappe; Stephen L Hoffman; Brandon K Sack; Claudia Daubenberger
Journal:  J Infect Dis       Date:  2018-04-23       Impact factor: 5.226

3.  Vaccine adjuvants CpG (oligodeoxynucleotides ODNs), MPL (3-O-deacylated monophosphoryl lipid A) and naloxone-enhanced Th1 immune response to the Plasmodium vivax recombinant thrombospondin-related adhesive protein (TRAP) in mice.

Authors:  Saeed Nazeri; Sedigheh Zakeri; Akram A Mehrizi; Navid D Djadid; Georges Snounou; Chiara Andolina; François Nosten
Journal:  Med Microbiol Immunol       Date:  2018-06-09       Impact factor: 3.402

4.  Sieve analysis using the number of infecting pathogens.

Authors:  Dean Follmann; Chiung-Yu Huang
Journal:  Biometrics       Date:  2017-12-14       Impact factor: 2.571

5.  Immunogenicity of full-length P. vivax rPvs48/45 protein formulations in BALB/c mice.

Authors:  Myriam Arévalo-Herrera; Kazutoyo Miura; Eduardo Solano; Juan Sebastián Ramírez; Carole A Long; Giampietro Corradin; Sócrates Herrera
Journal:  Vaccine       Date:  2021-11-19       Impact factor: 3.641

6.  High Level of Specific Anti-Plasmodium Falciparum Merozoite IgG1 Antibodies in Rural Asymptomatic Individuals of Dienga, South-Eastern Gabon.

Authors:  Irène Pegha-Moukandja; Roméo-Karl Imboumy-Limoukou; Nina Tchitoula-Makaya; Augustin-Ghislain Mouinga-Ondeme; Jean Claude Biteghe-Bi-Essone; Dieudonne Nkoghe Mba; Jean-Bernard Lekana-Douki; Fousseyni S Toure Ndouo
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2017-12-04

Review 7.  Characterization of T-cell immune responses in clinical trials of the candidate RTS,S malaria vaccine.

Authors:  Philippe Moris; Erik Jongert; Robbert G van der Most
Journal:  Hum Vaccin Immunother       Date:  2017-12-01       Impact factor: 3.452

8.  Predicting RTS,S Vaccine-Mediated Protection from Transcriptomes in a Malaria-Challenge Clinical Trial.

Authors:  Robert A van den Berg; Margherita Coccia; W Ripley Ballou; Kent E Kester; Christian F Ockenhouse; Johan Vekemans; Erik Jongert; Arnaud M Didierlaurent; Robbert G van der Most
Journal:  Front Immunol       Date:  2017-05-23       Impact factor: 7.561

Review 9.  malERA: An updated research agenda for diagnostics, drugs, vaccines, and vector control in malaria elimination and eradication.

Authors: 
Journal:  PLoS Med       Date:  2017-11-30       Impact factor: 11.069

10.  Establishing a controlled hookworm human infection (CHHI) model for Africa: A report from the stakeholders meeting held in Lambaréné, Gabon, November 10-11, 2019.

Authors:  Ayodele Alabi; Mosarrof Hussain; Marie-Astrid Hoogerwerf; Christine Ndong Mengome; Moses Egesa; Emmanuella Driciru; Linda J Wammes; Yvonne C M Kruize; Erliyani Sartono; Ayola Akim Adegnika; Peter G Kremsner; Maria Yazdanbakhsh; Selidji Todagbe Agnandji
Journal:  Arch Public Health       Date:  2021-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.